CIK 0001563880 · Non-accelerated filer<br>Smaller reporting company
Trevi Therapeutics, Inc.
Sign in to watch- Ticker
- TRVI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 450834299
- Phone
- 203-304-2499
- Business address
- 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN, CT, 06510
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $595,806
- in 1 filing, $596K under 10b5-1 plans
Net −$595,806. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-15 | Heffernan Michael Thomas Director | Option exercise 10b5-1 | +18,421 | $3.04 | $56K | 24,772 |
| 2026-09-15 | Heffernan Michael Thomas Director | Sale 10b5-1 | −18,321 | $15.09 | $276K | 6,451 |
| 2026-09-15 | Heffernan Michael Thomas Director | Sale 10b5-1 | −100 | $15.88 | $2K | 6,351 |
| 2026-09-15 | Heffernan Michael Thomas Director | Option exercise 10b5-1 | +21,052 | $3.33 | $70K | 27,403 |
| 2026-09-15 | Heffernan Michael Thomas Director | Sale 10b5-1 | −20,952 | $15.09 | $316K | 6,451 |
| 2026-09-15 | Heffernan Michael Thomas Director | Sale 10b5-1 | −100 | $15.88 | $2K | 6,351 |
| 2026-09-15 | Heffernan Michael Thomas Director | Option exercise · Stock Option (right to buy) 10b5-1 | −18,421 | 0 | ||
| 2026-09-15 | Heffernan Michael Thomas Director | Option exercise · Stock Option (right to buy) 10b5-1 | −21,052 | 0 | ||
| 2026-06-03 | Mathers Edward T Director | Grant or award · Nonstatutory Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2026-06-03 | Meeker David P Director | Grant or award · Nonstatutory Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2026-06-03 | VANLENT ANNE Director | Grant or award · Nonstatutory Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2026-06-03 | Colangelo Dominick Director | Grant or award · Nonstatutory Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2026-06-03 | Heffernan Michael Thomas Director | Grant or award · Nonstatutory Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2026-02-19 | Cassella James V Chief Development Officer | Grant or award · Stock Option (right to buy) | +215,000 | 215,000 | ||
| 2026-02-19 | Galletta Christopher See Remarks | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2026-02-19 | SCIASCIA THOMAS Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +85,000 | 85,000 | ||
| 2026-02-19 | GOOD JENNIFER L President & CEO | Grant or award · Stock Option (right to buy) | +675,000 | 675,000 | ||
| 2026-02-19 | Simon Farrell Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +160,000 | 160,000 | ||
| 2026-01-08 | HASTINGS DAVID C Chief Financial Officer | Grant or award · Stock Option (right to buy) | +375,000 | 375,000 | ||
| 2025-12-02 | Galletta Christopher See Remarks | Option exercise | +4,225 | $0.51 | $2K | 26,095 |
Page 1 of 9 · 179 trades